ArticleBMC psychiatry2026
IL-1α and CRP as key inflammatory mediators linking neuropathic pain, anxiety, and depression in major depressive disorder.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundIt's common comorbidity for Major Depressive Disorder (MDD), anxiety, and pain, underpinned by shared chronic inflammatory processes, this study aimed to identify etiological inflammatory biomarkers, focusing on MDD individuals with anxiety and pain symptoms.
methodsInitially, 218 participants underwent screening for this cross-sectional study. Ultimately, 75 first-episode drug-naive patients with MDD and 40 healthy controls met the inclusion criteria. Depression and anxiety symptoms were assessed by Hamilton Depression Rating Scale-24 (HAMD-24), Hamilton Anxiety Rating Scale-14 (HAMA-14), Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI), respectively. Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) and Prospective and Retrospective Memory Questionnaire (PRMQ) were to evaluate the pain feature and memory function respectively. Meso Scale Discovery was used to measure the amounts of eighteen cytokines and chemokines in peripheral blood. We use the sequential path model (model 6) and the moderated path model (model 59) in the PROCESS to examine the relationship between variables. A Gaussian Graphical Model (GGM), Gradient Boosted Regression (GBR) algorithm, SHapley Additive exPlanations (SHAP) values and Partial Dependence Plots (PDP) were used to visualize the primary features on model predictions.
resultsMDD patients displayed significantly higher IL-1α levels, lower CRP levels, greater pain sensitivity, and more cognitive impairment compared to controls. Multivariate regression confirmed a significant positive link between IL-1α and neuropathic pain (β = 0.25, p = 0.014). A sequential path model and a moderated path model revealed a crucial indirect pathway: IL-1α did not directly cause depressive symptoms but acted sequentially: IL-1α → neuropathic pain → subjective anxiety → depressive symptoms. High CRP levels exacerbated the relationship between anxiety and neuropathic pain. GBR analysis confirmed IL-1α as the most significant feature predicting pain.
conclusionsThe findings highlight IL-1α and CRP as key inflammatory markers associated with the relationship between pain, anxiety, and depressive symptoms. These results suggest the potential relevance of inflammation-related pathways in the clinical assessment of pain within the context of MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.